New product: Symkevi 50 mg/75 mg (tezacaftor/ivacaftor) film coated tablets
This new strength is licensed in combination regimen with ivacaftor tablets for treatment of patients with cystic fibrosis (CF) aged ≥6 years, who are homozygous for F508del mutation or who are heterozygous for F508del mutation and have one of specific mutations CFTR gene.
Source:
electronic Medicines compendium